Multiple-ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD9977 in healthy male subjects

Study identifier:D6401C00001

ClinicalTrials.gov identifier:NCT03435276

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Multiple-Ascending Dose Administration in Healthy Volunteers

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD9977

Sex

Male

Actual Enrollment

27

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 27 Feb 2018
Primary Completion Date: 13 Jun 2018
Study Completion Date: 13 Jun 2018

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria